01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
13:42 , Feb 12, 2019 |  BC Innovations  |  Translation in Brief

Stabilizing mutant proteins

A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy for treating diseases caused by loss-of-function protein mutations: target allosteric pockets on the mutant proteins to...
16:00 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Immunodeficiency Cell culture studies identified two allosteric stabilizers of mutant MALT1 that could help treat combined immunodeficiency in patients harboring the loss-of-function W580S mutation of MALT1, which results in low B cell counts. In...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
00:34 , Nov 21, 2018 |  BC Extra  |  Company News

Deal with Idorsia gives Santhera shot at second DMD candidate

In a deal that will make Idorsia Ltd. (SIX:IDIA) its largest shareholder, Santhera Pharmaceuticals Holding AG (SIX:SANN) gained an option to exclusively in-license a second Duchenne muscular dystrophy candidate: vamorolone (VBP15). Santhera CEO Thomas Meier...
20:11 , Apr 26, 2018 |  BC Innovations  |  Translation in Brief

Modulating metabolism in MS

Johns Hopkins University researchers showed in Science Tecfidera dimethyl fumarate blocks aerobic glycolysis by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH), shedding light on how the multiple sclerosis drug suppresses immune activation and suggesting metabolism as a target...
18:22 , Apr 13, 2018 |  BC Extra  |  Preclinical News

NCI identifies new lymphoma subtypes

A New England Journal of Medicine paper out of NIH's National Cancer Institute revealed new subtypes of diffuse large B cell lymphomas (DLBCL) that could lead to more targeted therapeutic strategies. The report adds to...
17:17 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Reata reports Phase II data for omaveloxolone in mitochondrial myopathies

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported top-line data from the Phase II MOTOR trial in 53 patients with mitochondrial myopathies showing that omaveloxolone (oral RTA 408) missed the primary endpoint of improving peak workload during exercise...
15:03 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
17:33 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Catabasis reports 60-week data for edasalonexent in DMD

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the U.S. Phase I/II MoveDMD trial in steroid-naïve Duchenne muscular...